DRIVIN G ROWTH - Dr. Reddy's

More documents

Recommendations

Info

32 intangibles accounting market value added “MARKET VALUE ADDED” is a supplementary technique used to evaluate a company’s performance in stakeholder value creation. Market Value Added (MVA) is the excess of the market value of the Company over the value of investors’ capital. In contrast to the economic profit, Table 3 | MVA–Market Value Added RS. IN MILLION which is the value added by the Company over a given period, the MVA is a measure of the investor’s perception of value added. MVA: Current Market Value of Debt & Equity – Book value of Debt & Equity. 2002 2001 2000 1999 Current Market Value of debt 138 3754 3963 3021 No of O/s shares ( Mn) 77 32 32 32 Share price details High for 2001-02 1150 1494 1500 616 Low for 2001-02 * 432 1159 939 396 Average price 2001-02 791 1327 1213 506 Average market value of equity 60527 41992 38391 16011 Market value of debt & equity 60666 45746 42354 19032 Book value of debt & equity 14718 9287 8731 7226 Market Value Added 45948 36459 33623 11806 * High price recorded in November 2001 post stock split. Low recorded in April 2001 – adjusted for stock split DR. REDDY’S LABORATORIES LTD. | INTANGIBLES ACCOUNTING | ANNUAL REPORT 2001-2002
total shareholder’s return “TOTAL SHAREHOLDER’S RETURN” (TSR) represents the change in capital value of a company over a period of one year, plus dividends, expressed as a % of gain or loss of the beginning capital value. To bring in more accuracy into measuring the Total Shareholders’ Return, the debt component has been eliminated from the capital value. Table 4 | TSR–Total Shareholders Return RS. IN MILLION 2002 2001 2000 1999 Closing capital value 14580 5533 4768 4205 Beginning capital value * 11315 4768 4205 3616 Additions 3265 764 563 589 Dividend 574 126 122 122 Total * Adjusted for share capital increase in 2001-2002 33.9% 18.7% 16.3% 19.7% DR. REDDY’S LABORATORIES LTD. | INTANGIBLES ACCOUNTING | ANNUAL REPORT 2001-2002 33
Page 1 and 2: DRIVIN G ROWTH Dr. Reddy’s Labora
Page 3 and 4: sales of branded formulations grew
Page 5 and 6: THE ULTIMATE ACCOLADE FOR A PHARMAC
Page 7 and 8: IT TAKES COURAGE AND VISION TO LOOK
Page 9 and 10: 1997 Entered: Phase I clinical tria
Page 11 and 12: 1987 USFDA Inspection: Ibuprofen fa
Page 13 and 14: 1999 Submitted: ANDA for Omeprazole
Page 15 and 16: 1995 Established: Reddy- Biomed; ou
Page 17 and 18: ARMED WITH A HIGHLY MOTIVATED AND C
Page 19 and 20: K ILO L AB FACILITY at Technology D
Page 21 and 22: SHE PRACTICES HAVE EVOLVED FROM AN
Page 23 and 24: ADOPTING A COMPETENCY-BASED FRAMEWO
Page 25 and 26: THE HIGHEST PATRIOTISM AND PHILANTH
Page 27 and 28: AFTER AN HOUR AT ROSHNI I LEFT WITH
Page 29: and valuation THE DICTUM in any kno
Page 33 and 34: 4,585,070 equity shares of erstwhil
Page 35 and 36: REDDY PHARMACEUTICALS HONG KONG LTD
Page 37 and 38: Pathway enables Reddy US Therapeuti
Page 39 and 40: AUDITORS THE AUDIT in the financial
Page 41 and 42: 2.Benefits derived as a result of t
Page 43 and 44: Table B | Technology, absorption, a
Page 45 and 46: articulation of its corporate visio
Page 47 and 48: THE LAUNCH OF FLUOXETINE HAS BEEN T
Page 49 and 50: MUCH OF THE CASH FLOW ARISING OUT O
Page 51 and 52: WITH THE ANTICIPATED GROWTH IN THE
Page 53 and 54: CHART B NCE Pipeline Diabetes DRF N
Page 55 and 56: AURIGENE WILL BUILD SKILLS IN AUTOM
Page 57 and 58: The highlights of the scheme were:
Page 59 and 60: INVESTMENTS INVESTMENTS reduced to
Page 61 and 62: Rs. 108 million (US$ 2.25 million)
Page 63 and 64: THE STRENGTH OF INDIA’S SCIENTIFI
Page 65 and 66: internal accounting, administrative
Page 67 and 68: e disproportionately distributed in
Page 69 and 70: COMPOSITION AND MEETINGS OF THE BOA
Page 71 and 72: Table 2 | Remuneration of the direc
Page 73 and 74: (iii) Ms. G Anuradha (daughter of D
Page 75 and 76: increase speed of reporting and cre
Page 77 and 78: the Committee. The Investment Commi
Page 79 and 80: MANAGEMENT DISCUSSION AND ANALYSIS
Page 81 and 82:
non-executive, independent Addition
Page 83 and 84:
press releases and conducts program
Page 85 and 86:
We state that no investor grievance
Page 87 and 88:
Media Bhaswati Banerjee / R. Rammoh
Page 89 and 90:
CODES AT VARIOUS STOCK EXCHANGES Th
Page 91 and 92:
EQUITY HISTORY OF THE COMPANY Table
Page 93 and 94:
SHAREHOLDING PATTERN AS ON MARCH 31
Page 95 and 96:
dematerialised form may contact the
Page 97 and 98:
UNCLAIMED DIVIDENDS Pursuant to sec
Page 99 and 100:
generics Survey No. 41 Bachupally Q
Page 101 and 102:
financials 103
Page 103 and 104:
annexure to the auditors’ report
Page 105 and 106:
alance sheet | AS AT MARCH 31 (All
Page 107 and 108:
schedules to the balance sheet | (A
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
schedules to the profit and loss ac
Page 119 and 120:
schedule to the balance sheet and p
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
cash flow statement | YEAR ENDED MA
Page 133 and 134:
auditors’ certificate To The Boar
Page 135 and 136:
consolidated financials
Page 137 and 138:
consolidated balance sheet | (All a
Page 139 and 140:
schedules to the consolidated balan
Page 141 and 142:
Page 143 and 144:
Page 145 and 146:
schedules to the consolidated profi
Page 147 and 148:
schedule to the consolidated balanc
Page 149 and 150:
Page 151 and 152:
Page 153 and 154:
Page 155 and 156:
Page 157 and 158:
Page 159 and 160:
Page 161 and 162:
cash flow statement | (contd...) YE
Page 163 and 164:
statement under section 212
Page 165 and 166:
The net Aggregate of profits (losse
Page 167 and 168:
drl investments ltd.
Page 169 and 170:
auditors’ report A RAMACHANDRA RA
Page 171 and 172:
alance sheet | AS Schedule 2002 200
Page 173 and 174:
schedules | AS AT MARCH 31 (Rs) 200
Page 175 and 176:
schedules Schedule - 3.00 NOTES TO
Page 177 and 178:
compact electric ltd.
Page 179 and 180:
Page 181 and 182:
alance sheet | AS Schedule 2002 200
Page 183 and 184:
Page 185 and 186:
Page 187 and 188:
schedules | FOR THE YEAR ENDED MARC
Page 189 and 190:
schedules 7. The information requir
Page 191 and 192:
alance sheet abstract and company
Page 193 and 194:
eddy pharmaceuticals hong kong ltd.
Page 195 and 196:
eport of the auditors ERNST & YOUNG
Page 197 and 198:
profit and loss account | YEAR ENDE
Page 199 and 200:
notes to financial statements - DEC
Page 201 and 202:
notes to financial statements - DEC
Page 203 and 204:
eddy biomed ltd.
Page 205 and 206:
eport of sinay joint-stock company
Page 207 and 208:
alance sheet | AS AT DECEMBER 31 (R
Page 209 and 210:
eddy antilles n.v.
Page 211 and 212:
alance sheet | AS AT DECEMBER 31 (U
Page 213 and 214:
notes to the financial statements G
Page 215 and 216:
dr. reddy’s farmacêutica do bras
Page 217 and 218:
dr. reddy’s laboratories, inc.
Page 219 and 220:
alance sheet | AS AT MARCH 31 (US $
Page 221 and 222:
statement of cash flows | FOR THE Y
Page 223 and 224:
notes to the financial statements n
Page 225 and 226:
notes to the financial statements n
Page 227 and 228:
eddy pharmaceuticals singapore pte
Page 229 and 230:
9. DIVIDENDS No dividend has been p
Page 231 and 232:
eport of the auditors to the member
Page 233 and 234:
profit and loss statement | FOR sta
Page 235 and 236:
notes to the financial statements -
Page 237 and 238:
notes to the financial statements -
Page 239 and 240:
eddy us therapeutics, inc
Page 241 and 242:
alance sheet | AS AT MARCH 31 (US $
Page 243 and 244:
statement of cash flows | FOR THE Y
Page 245 and 246:
notes to financial statements 2.REL
Page 247 and 248:
eddy cheminor s.a.
Page 249 and 250:
alance sheet | Euros March 31, Fisc
Page 251 and 252:
profit and loss account | FOR THE Y
Page 253 and 254:
accounting rules and methods Annexe
Page 255 and 256:
depreciation | AS Categories A Posi
Page 257 and 258:
ageing analysis of debts receivable
Page 259 and 260:
details of charges to be paid | AS
Page 261 and 262:
effect of different fiscal provisio
Page 263 and 264:
B - Agreements with Mr Luc Lamiraul
Page 265 and 266:
cheminor investments ltd.
Page 267 and 268:
Page 269 and 270:
alance sheet | AS AT MARCH 31 Parti
Page 271 and 272:
schedules forming part of balance s
Page 273 and 274:
alance sheet abstract and company
Page 275 and 276:
aurigene discovery technologies ltd
Page 277 and 278:
Acknowledgements The Directors take
Page 279 and 280:
annexure to the auditors’ report
Page 281 and 282:
profit and loss account | FOR EXPEN
Page 283 and 284:
schedules forming part of the profi
Page 285 and 286:
schedules forming part of the balan
Page 287 and 288:
zenovus biotech pvt. ltd.
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
kunshan rotam reddy pharmaceutical
Page 297 and 298:
alance sheet | AS AT DECEMBER 31 (R
Page 299 and 300:
income statement | FOR THE YEAR END
Page 301 and 302:
notes to the financial statements 5
Page 303 and 304:
eddy netherlands b.v.
Page 305 and 306:
alance sheet | AS AT DECEMBER 31 (I
Page 307 and 308:
general notes GENERAL COMMENTS The
Page 309 and 310:
notice
Page 311 and 312:
The remuneration payable by way of
Page 313 and 314:
Item No. 9 The Company had appointe
show all

DRIVIN G ROWTH - Dr. Reddy's

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?